Chief Executive Officer & Co-Founder

SVP Discovery

BioTech Engitix lands €21 mn extension to push ECM cancer therapies

Engitix secures £18.6m to advance cancer and fibrosis therapies

Engitix adds $25m to fuel ECM-driven push in cancer and fibrosis

Engitix raises £20m Series A extension from Netherton Investments to develop therapies for cancer and fibrosis

ML/AI Research Scientist

Engitix Therapeutics is a London-based biotechnology company unlocking the extracellular matrix (ECM) as a source of novel therapeutic targets for fibrosis and cancer. They are seeking an ML/AI Research Scientist to lead the design and development of foundational models for proteomics analysis, focusing on mass spectrometry data and improving peptide identification and discovery of novel biology.